Evidence Grade B — Strong clinical evidence. 410 published studies, 248 human. 36 registered clinical trials.
Medically reviewed by a licensed medical professional
Carbetocin is a long-acting version of oxytocin that has been studied to prevent dangerous bleeding after childbirth. It is registered in over 80 countries outside the US but has never received FDA approval. A heat-stable formulation — one that does not need refrigeration — was added to the WHO Essential Medicines List, addressing a critical need in tropical and low-resource settings where standard oxytocin degrades in the heat.
Carbetocin is also known by these brand and alternate names:
410 published studies: 248 human, 73 animal, 17 in-vitro, 75 reviews
Carbetocin has not been approved by the FDA. It is registered in over 80 countries for prevention of uterine atony and excessive bleeding after caesarean delivery. A heat-stable formulation was added to the WHO Essential Medicines List in 2019.
The CHAMPION trial (WHO, 2018; over 29,000 women) compared a heat-stable carbetocin formulation to oxytocin for preventing postpartum haemorrhage after vaginal delivery, and found it to be non-inferior. The heat-stable formulation addresses a significant limitation of oxytocin, which degrades in warm climates without refrigeration — a major concern in low-resource settings where postpartum haemorrhage causes the most deaths. Its regulatory status varies by jurisdiction.
Carbetocin activates the same oxytocin receptor as natural oxytocin, producing uterine contractions. Its molecular structure includes a modification that prevents the body from breaking it down as quickly as natural oxytocin, extending its duration of action to approximately 40 minutes compared to oxytocin's 3–17 minutes. This longer action means a single dose may be sufficient where oxytocin would require a continuous infusion.
The WHO-sponsored CHAMPION trial (over 29,000 women) found heat-stable carbetocin non-inferior to oxytocin for preventing postpartum haemorrhage after vaginal delivery. This matters because standard oxytocin requires refrigeration, which is often unreliable in the regions where postpartum haemorrhage is the leading cause of maternal death. The US market has not been pursued, likely because reliable cold-chain oxytocin is ubiquitous in US healthcare facilities. A development programme for Prader-Willi syndrome (a genetic condition) failed, closing the most advanced pathway for major-market development. Carbetocin's global health significance rests on the heat-stable formulation for resource-limited settings.
PeptideTrace tracks 36 registered clinical trials for Carbetocin sourced from ClinicalTrials.gov.
Effect of Co-administration of Carbetocin and Calcium Chloride on Uterine Tone in Patients Undergoing Elective Cesarean Delivery
Cardiac Changes After Effective Dose Carbetocin for Elective Caesarian Section
Timing of Carbetocin Administration in Postpartum Hemorrhage
OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Health Canada Market Authorisation
Carbetocin (1-deamino-1-monocarba oxytocin) is a long-acting synthetic oxytocin analogue in which the disulfide bridge is replaced with a thioether linkage, preventing enzymatic reduction and extending the half-life to approximately 40 minutes (versus 3–5 minutes for oxytocin). It has never been approved by the FDA.
Carbetocin activates the oxytocin receptor (OXTR) via the same Gq/PLC/IP3 signaling pathway as oxytocin, producing uterine smooth muscle contraction. The thioether modification provides extended receptor occupancy and a longer duration of uterotonic action compared to oxytocin, enabling single-dose administration for PPH prevention rather than the continuous infusion required with oxytocin.
Carbetocin has never been FDA-approved in the United States. It is registered in over 80 countries for prevention of postpartum hemorrhage following cesarean delivery. A heat-stable formulation was added to the WHO Essential Medicines List in 2019, addressing the cold-chain limitation of oxytocin in low-resource settings. The WHO CHAMPION trial (~30,000 women across 10 countries) demonstrated carbetocin was non-inferior to oxytocin for PPH prevention. Acadia Pharmaceuticals pursued intranasal carbetocin for Prader-Willi syndrome (hyperphagia), but the Phase 3 COMPASS PWS trial failed its primary endpoint in September 2025, and Acadia announced discontinuation of the program.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Nafarelin is marketed as Synarel (approved 1990) for endometriosis and central precocious puberty. It requires administration as one spray in each nostril twice daily — a higher frequency than injectable alternatives but avoids needles entirely, which can be a significant advantage for some patients, particularly children. Clinical trials showed symptom improvement in 75–92% of endometriosis patients. However, absorption can be affected by nasal congestion or concurrent use of nasal decongestants, which can be a practical limitation. As with all GnRH agonists, prolonged use leads to bone density loss, and treatment for endometriosis is typically limited to six months. Nafarelin occupies a niche for patients who prefer non-injectable hormone suppression, though it has become less commonly prescribed as longer-acting depot injections and oral alternatives have become available.
Triptorelin is marketed as Trelstar (approved 2000) for advanced prostate cancer, available as intramuscular depot injections in monthly (3.75 mg), three-monthly (11.25 mg), and six-monthly (22.5 mg) formulations. It is also widely used internationally for gender-affirming care and central precocious puberty. Triptorelin is one of the most commonly used GnRH agonists globally, though it faces the same competitive pressure as other agents in this class from newer oral GnRH antagonists like relugolix, which avoid the initial hormone flare and offer potential cardiovascular advantages. Clinical data demonstrate reliable testosterone suppression comparable to other GnRH agonists in this class.
Histrelin is available as Supprelin LA for central precocious puberty (approved 2007). The Vantas implant for prostate cancer was approved in 2004 but discontinued in 2021. The implant requires a minor surgical procedure for insertion and removal/replacement each year. Supprelin LA's main clinical advantage is its 12-month duration — the longest of any GnRH agonist — which is particularly valuable in paediatric patients where treatment compliance over years is important. Clinical studies demonstrated effective suppression of puberty markers in over 97% of patients. The implant has also seen significant off-label use in gender-affirming care as a puberty blocker, where its annual dosing schedule offers practical benefits for adolescent patients and their families.
Deep Dives
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
